Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Autoimmun. 2020 Sep 17;115:102543. doi: 10.1016/j.jaut.2020.102543

Fig. 2. RI-CT and RI-EXT inhibit the binding of InsB:9-23 to HLA-DQ8 expressed on BSM cells.

Fig. 2.

(A-E) HLA-DQ8 expression on BSM cells was evaluated using a PE-DQ8 antibody (PE-labeled IgG antibody was used as negative control), and APC-streptavidin was used to detect the peptide binding (cells double positive for PE and APC are shown in the upper-right quadrant). (A) and (B) BSM cells were loaded or not with InsB:9-23 in the presence of (C) and (D) RI-CT and RI-EXT. Inhibition of binding was analyzed by flow cytometry; cells were gated on live BSM cells. Both RI-D-peptides significantly blocked the binding between InsB:9-23 and HLA-DQ8 expressed on BSM cells. (E) Dose-dependent InsB:9-23 binding to HLA-DQ8 molecule. Bars represent mean ± SEM from 3 independent experiments. *p < 0.001; ***p < 0.001, by Student’s t-test.